BL-8040 Peptide Composition Stability and Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions of BL-8040, a peptide used in treating conditions like cancer and arthritis, lack optimal formulations that enhance its biological activity and stability.
Innovation Solution
A composition-of-matter comprising BL-8040 and at least one compound with a relative retention time in the range of 0.86 to 0.88, or 0.71 to 0.73, which are determined using specific HPLC conditions, enhancing the peptide's biological activity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BL-8040 is formulated as a standalone pharmaceutical composition, then the formulation is simple, but the biological activity and stability are suboptimal
Solution Approach 1:
The patent applies composite materials by combining BL-8040 peptide with specific compounds (retention time 0.86-0.88 or 0.71-0.73) to create a composite pharmaceutical formulation. This composite approach enhances the biological activity and stability of the peptide while managing the complexity through defined compositional ratios
Solution Approach 2:
The patent employs parameter changes by optimizing the concentration ratios of BL-8040 to the accompanying compounds within specific ranges (0.075%-0.225% for RT 0.86-0.88 compounds, and 10% or more for RT 0.71-0.73 compounds). These parameter optimizations enhance biological activity while controlling formulation complexity
2Stability of the object's composition
If BL-8040 is formulated as a standalone pharmaceutical composition, then the formulation is simple, but the stability is suboptimal
Solution Approach 1:
The patent uses composite materials by formulating BL-8040 with specific stabilizing compounds (identified by retention times 0.86-0.88 and 0.71-0.73). This composite formulation enhances peptide stability through synergistic interactions while maintaining controlled complexity through defined compositional parameters
Solution Approach 2:
The patent incorporates compounds with specific retention times that act as stabilizing agents, potentially replacing the need for complex preservation systems. These compounds provide stability enhancement without requiring elaborate formulation strategies
3Reliability
If BL-8040 is used without specific compound combinations, then the treatment protocol is simple, but the treatment efficacy is suboptimal
Solution Approach 1:
The patent enhances treatment efficacy by creating composite pharmaceutical compositions containing BL-8040 combined with specific compounds (retention time 0.86-0.88 at 0.075%-0.225% concentration ratio, or retention time 0.71-0.73 at 10% or more concentration ratio). This composite approach produces synergistic therapeutic effects while managing composition complexity through well-defined parameters
Data Source
AI summary
A composition comprising BL-8040 (SEQ ID NO: 1) is disclosed herein, which may be for use in treating a condition treatable by BL-8040. The composition further comprises at least one compound characterized by a relative retention time of from 0.86 to 0.88 and/or a relative retention time of from 0.71 to 0.73 (wherein a relative retention time of BL-8040 is 1) under conditions described herein.